The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer
source: pixabay.com

The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer

Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…

Continue Reading The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer
Data Ownership as Leverage in Accelerating Rare Disease Drug Development
source: pixabay.com

Data Ownership as Leverage in Accelerating Rare Disease Drug Development

Patient groups can optimize patient registries, cross-sectional studies, and/or longitudinal natural history studies to maximize collaborations with sponsors of orphan drugs and gene therapies. Written by Harsha Rajasimha, MS, PhD…

Continue Reading Data Ownership as Leverage in Accelerating Rare Disease Drug Development